Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
84
resultados
Última actualización
30/11/2025 [07:08:00]
Resumen de: US2025360189A1
An immunogenic gel compositions for oral administration and methods of immunizing an animal the methods including administering to the animal a therapeutically effective amount of an immunogenic gel composition comprising an antigen of an animal pathogen and a gel composition for oral administration.
Resumen de: WO2025238284A1
The present invention relates to a DNA construct that codes for a fusion protein comprising at least two enterohemorrhagic Escherichia coli antigens, for example, the antigens Int280, EspB, EspA, Stx2B, EspD, combinations or fragments thereof, vectors, fusion protein, immunisation methods and vaccines. The coded antigens can be fused Int280 and EspB of enterohemorrhagic Escherichia coli, forming a fusion protein with or without a connecting sequence between the two. The fused antigens can show the amino acid sequence SEQ ID No. 3 or SEQ ID No. 4 and are coded by the nucleotide sequence in SEQ ID No. 1 and SEQ ID No. 2. The construct can also comprise a signal sequence and a binding sequence for binding to the membrane of bacteria.
Resumen de: WO2025236040A1
Disclosed herein are solid lipid nanoparticles comprising a fatty acid esterified with polyethylene glycol. The polyethylene glycol is functionalised with an aptamer (i.e. targeting ligand). The nanoparticle may be loaded with an antibiotic or an antifungal, and a fluorescent compound. Also provided are their methods of preparation and their use in drug delivery and biosensing.
Resumen de: CN120202300A
The present invention relates to a DNA construct comprising: a gene encoding flagellin and a gene encoding an immunopotentiator (or adjuvant) protein. In order to achieve effective cancer treatment by selectively killing only cancer cells, the attenuated Salmonella strains of the present disclosure are designed to produce immunogenic substances in cancer tissue to induce a strong anti-cancer immune response to significantly inhibit tumor size in primary and metastatic cancers. Therefore, the strain can be advantageously used in a prophylactic or therapeutic composition for increasing survival rate.
Resumen de: MX2025009500A
The invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition that is intended for mammals and birds and comprises a killed whole bacterium, said bacterium being covered with a cationic agent, in particular cationic nanoparticles.
Resumen de: CN117838855A
The invention relates to a synthetic adhesive for limiting passage through mucus. Synthetic adhesives for reducing the proportion of targets that can traverse mucus and/or free cleavage are disclosed, as well as methods of using these synthetic adhesives to reduce mucosal penetration and/or free cleavage of targets.
Resumen de: CN120418260A
The present disclosure generally relates to improved methods for preparing glycoconjugates. The method includes conjugating a saccharide to a carrier protein using an acetoxyborohydride-containing reducing mixture prepared in situ.
Resumen de: US2025345369A1
Provided are delivery immunostimulatory bacteria that have enhanced colonization of tumors, the tumor microenvironment and/or tumor-resident immune cells, and enhanced anti-tumor activity. The immunostimulatory bacteria are modified by deletion of genes encoding the flagella, or by modification of the genes so that functional flagella are not produced, and/or are modified by deletion of pagP or modification of pagP to produce inactive PagP product. As a result, the immunostimulatory bacteria are flagellin and/or pagP−. The immunostimulatory bacteria optionally have additional genomic modifications so that the bacteria are adenosine or purine auxotrophs. The bacteria optionally are one or more of asd−, purI−, and msbB−. The immunostimulatory bacteria, such as Salmonella species, are modified to encode immunostimulatory proteins that confer anti-tumor activity in the tumor microenvironment, and/or are modified so that the bacteria preferentially infect immune cells in the tumor microenvironment, or tumor-resident immune cells, and/or are modified to induce less cell death in immune cells than in other cells. Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the immunostimulatory bacteria.
Resumen de: WO2025233323A1
The invention relates to compositions of binding peptides, and individual binding peptides, capable of specific binding to either of two variants of OmpA occurring in pathogenic E. coli, and to methods employing these binding peptides for detection or isolation of pathogenic E. coli.
Resumen de: MX2025009214A
The invention relates to protein bacteriocins (PBs) as therapeutic agents, and specifically to protein complexes comprising two or more PB molecules associated with a protein scaffold which comprises cognate immunity protein domains for the effector portions of the respective PBs. In particular, the invention provides an anti-bacterial protein complex comprising (a) a first PB molecule and a second PB molecule; and (b) an immunity protein scaffold comprising a first immunity protein domain and a second immunity protein domain; wherein the first and second immunity protein domains are non-covalently bound to the respective first and second PB molecules.
Resumen de: CN120924562A
本发明公开了一种马链球菌和马流产沙门菌二联融合抗原，其核苷酸序列如SEQ ID NO.1所示。本发明将马流产沙门菌的FljB与马链球菌的SeM、EAG、GAPDH部分抗原串联重组在一起，不仅可以同时预防马链球菌和马流产沙门菌2种不同的马传染病，还增强了小鼠的体液免疫应答水平，利用该融合抗原免疫可获得抵抗马链球菌和马流产沙门菌的攻毒保护效果，高于单独抗原蛋白的免疫和灭活全菌的免疫，这解决了以往灭活疫苗免疫效率低和免疫繁琐的问题，有利于降低免疫的成本。
Resumen de: MX2025009214A
The invention relates to protein bacteriocins (PBs) as therapeutic agents, and specifically to protein complexes comprising two or more PB molecules associated with a protein scaffold which comprises cognate immunity protein domains for the effector portions of the respective PBs. In particular, the invention provides an anti-bacterial protein complex comprising (a) a first PB molecule and a second PB molecule; and (b) an immunity protein scaffold comprising a first immunity protein domain and a second immunity protein domain; wherein the first and second immunity protein domains are non-covalently bound to the respective first and second PB molecules.
Resumen de: WO2025227308A1
A phage lyase with an amino acid sequence set forth in SEQ IN NO.2. The lyase can inhibit the growth of Staphylococcus, Escherichia, Klebsiella, and Salmonella bacteria, and can be used as an antibacterial substance in milk pollution control, belonging to the field of bioengineering. The phage lyase can be used for preparing an enzyme formulation alone or in a compounded manner to specifically inactivate bacteria such as Staphylococcus aureus, thereby providing an enzyme formulation source which is safe and free of toxic and side effects for controlling Staphylococcus aureus pollution in milk at present.
Resumen de: US2022125906A1
Compositions and methods for the treatment of benign nervous system tumors including schwannomas using attenuated Salmonella typhimurium and optionally one or more checkpoint inhibitors.
Resumen de: KR20230091594A
The present invention relates to a Salmonella mutant strain expressing anti-PD-L1 peptide, outer membrane vesicles thereof, and a pharmaceutical composition containing the same. The Salmonella mutant strain expresses the anti-PD-L1 peptide in an extracellular loop of an outer membrane protein A, and thus, the anti-PD-L1 peptide can be delivered stably and efficiently to the inside of the tumor due to the characteristics of Salmonella, and can exhibit an anti-tumor effect by inducing the activation of T cells through the formation of a bond with PD-1 of cancer cells, thereby using the Salmonella mutant strain or the membrane vesicles thereof for cancer treatment.
Resumen de: MX2025009214A
The invention relates to protein bacteriocins (PBs) as therapeutic agents, and specifically to protein complexes comprising two or more PB molecules associated with a protein scaffold which comprises cognate immunity protein domains for the effector portions of the respective PBs. In particular, the invention provides an anti-bacterial protein complex comprising (a) a first PB molecule and a second PB molecule; and (b) an immunity protein scaffold comprising a first immunity protein domain and a second immunity protein domain; wherein the first and second immunity protein domains are non-covalently bound to the respective first and second PB molecules.
Resumen de: WO2025224268A1
The present invention relates to a live attenuated Gram-negative bacterium modified to enable enhanced vacuole escape. In particular, the invention relates to a live attenuated Gram-negative bacterium comprising a heterologous polynucleotide encoding a prokaryotic disulfide bond isomerase, or functional fragment thereof, wherein said heterologous polynucleotide encoding the prokaryotic disulfide bond isomerase is operably linked to a promoter, or a live attenuated Gram-negative bacterium comprising an endogenous prokaryotic disulfide bond isomerase, or functional fragment thereof, wherein the endogenous prokaryotic disulfide bond isomerase is upregulated compared to its basal level expression.
Resumen de: WO2025224251A1
The present invention relates to a live attenuated Gram-negative bacterium comprising a modified hlyCABD operon, wherein the modified hlyCABD operon is split into a first segment and a second segment, the first segment being operably linked to a first independently controlled promoter, wherein the first independently controlled promoter is a strong constitutive promoter or a strong vacuole-induced promoter, and the second segment being operably linked to a second independently controlled promoter, wherein the second independently controlled promoter is a strong vacuole-induced promoter, and wherein the first segment comprises a heterologous polynucleotide encoding a lysin upstream of a hlyAs translocation sequence, wherein the heterologous polynucleotide encoding one or more cargo molecules replaces a hlyA gene, and wherein the second segment comprises hly genes involved in secretion.
Resumen de: WO2025224621A1
Time sensitive biopharmaceutical processing updates can be implemented using lateral flow devices to test on-site during manufacturing. Lateral flow testing for an analyte such as, for example, impurities (e.g., host cell proteins), during manufacturing of a biopharmaceutical drug product is completed within twenty-five minutes of collecting a sample from the manufacturing line. That is, all sample preparation, such as adding reagent or diluting the sample, contacting the prepared sample to a lateral flow device, and detecting presence or absence of the analyte is completed within twenty-five minutes (e.g., 20 minutes, 18 minutes, 15 minutes) from collection such that processing adjustments during manufacturing can be implemented.
Resumen de: KR20250155130A
본 발명은 서울특별시 서울기술연구원 2022년도 캠퍼스타운 기술매칭 지원사업(반려동물 장내미생물 자가검사키트)을 통해 개발된 기술이다. 본 발명은 동물의 장내미생물 검출용 조성물 또는 키트에 관한 것으로서, 본 발명의 조성물 또는 키트는 미생물 유래 독소에 특이적으로 결합할 수 있는 물질을 프로브로 포함함으로써, 시중에 널리 사용되는 코로나 자가검진 키트와 마찬가지로 소비자 스스로 반려동물의 장내미생물을 검사할 수 있도록 하고, 이에 따라 반려동물의 장내미생물 분석에 대한 소비자 접근성을 크게 향상시킬 수 있다.
Resumen de: AU2024264505A1
Provided are non-naturally occurring systems, methods, and compositions for the detection of microbes. The disclosure relates to the detection of an antigen specific to a microbe, such as a foodborne, an environment-borne, and a bloodborne bacteria, using capture antibody and moiety, detector antibody and moiety, and a light-emitting particle.
Resumen de: US2025334572A1
Time sensitive biopharmaceutical processing updates can be implemented using lateral flow devices to test on-site during manufacturing. Lateral flow testing for an analyte such as, for example, impurities (e.g., host cell proteins), during manufacturing of a biopharmaceutical drug product is completed within twenty-five minutes of collecting a sample from the manufacturing line. That is, all sample preparation, such as adding reagent or diluting the sample, contacting the prepared sample to a lateral flow device, and detecting presence or absence of the analyte is completed within twenty-five minutes (e.g., 20 minutes, 18 minutes, 15 minutes) from collection such that processing adjustments during manufacturing can be implemented.
Resumen de: WO2025225874A1
The present invention relates to a method for detecting live foodborne pathogens using novel bacteriophages LEC1, LBC9, and LSE2. By using this method, Escherichia coli, Bacillus cereus, and Salmonella spp., which are live foodborne pathogens in food, can be rapidly and accurately detected at the same time, and thus the method can be effectively used for preventing food poisoning.
Resumen de: EP4641200A2
Disclosed herein are methods and systems for rapid detection of microorganisms such as Listeria spp. in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as Listeria-specific bacteriophage, allows detection of a specific microorganism, such as Listeria spp. and an indicator signal may be amplified to optimize assay sensitivity.
Nº publicación: EP4637794A2 29/10/2025
Solicitante:
PURDUE RESEARCH FOUNDATION [US]
UR REHMAN SHAFIQ [PK]
HAYAT ZAFAR [PK]
Purdue Research Foundation,
Ur Rehman, Shafiq,
Hayat, Zafar
Resumen de: WO2024137831A2
A composition of bacteriophages comprising at least one phage selected from TTS1, TTS2, TTS3, TTS4, TTS5, and TTS6, wherein the phages are optionally encapsulated; and a method for preventing or treating an infection caused by Salmonella Gallinarum by administering to a subject a therapeutically effective amount of the composition.
BOPI
Sede Electrónica
